XTX Topco’s Black Diamond Therapeutics BDTX Stock Holding History

XTX Topco’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82K	Sell	44,301 -8,539	-16%	-$20.9K	﹤0.01%	3585
2026 Q1	$113K	Sell	52,840 -66,839	-56%	-$159K	﹤0.01%	3070
2025 Q4	$291K	Sell	119,679 -96,516	-45%	-$342K	0.01%	2098
2025 Q3	$819K	Buy	216,195 +36,961	+21%	+$108K	0.04%	705
2025 Q2	$445K	Buy	179,234 +137,036	+325%	+$264K	0.02%	1181
2025 Q1	$65.4K	Sell	42,198 -49,724	-54%	-$104K	﹤0.01%	1949
2024 Q4	$197K	Buy	+91,922	New	+$263K	0.02%	1567
2024 Q2	–	Sell	-12,416	Closed	-$62.9K	–	1872
2024 Q1	$62.9K	Buy	+12,416	New	+$50.1K	0.01%	1437
2021 Q3	–	Sell	-19,863	Closed	-$242K	–	695
2021 Q2	$242K	Buy	+19,863	New	+$393K	0.08%	475

Other funds holding BDTX

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

XTX Topco's BDTX Position: Q2 2026 in Review

XTX Topco reduced its Black Diamond Therapeutics (BDTX) stake by 16% in Q2 2026, selling an estimated $20.9K and leaving 44,301 shares worth $82K. The position accounts for ﹤0.01% of the portfolio, ranked #3585.

XTX Topco first reported a position in BDTX in Q2 2021 and has held it in 9 quarters since. The position peaked at $819K in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

XTX Topco held 44,301 shares of Black Diamond Therapeutics worth $82K as of Q2 2026.
XTX Topco sold 8,539 Black Diamond Therapeutics shares in Q2 2026, an estimated $20.9K.
Black Diamond Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3585 holding.
XTX Topco first reported a position in Black Diamond Therapeutics in Q2 2021 and has held it in 9 quarters since.
XTX Topco's Black Diamond Therapeutics position peaked at $819K in Q3 2025.
96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.